[{"data":1,"prerenderedAt":23},["ShallowReactive",2],{"$faC0dp89kTQNcI_T_RnL37oEM0Ge8afRdv6kfkNeoE44":3},{"card":4,"examId":6,"chapterTitle":20,"prev":21,"next":22},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":12,"explanation":13,"explanationDetail":14,"mistakeHint":14,"lectureRef":14,"storyRef":14,"chapterSlug":15,"sectionCode":16,"sectionTitle":17,"clusterSlug":18,"term":14,"sequenceOrder":14,"regionWeight":14,"revisionMark":14,"isActive":19},"ch5-044","touhan","副作用情報の調査検討は総合機構において専門委員の意見を聴きながら行われる。",0,[10,11],"正しい","誤り","ox","各制度で集められた副作用情報は、総合機構（PMDA）において専門委員の意見を聴きながら調査・検討が行われます。その結果をもとに厚生労働大臣が必要な措置を講じます。",null,"chapter-5","5-II-2","副作用情報等の評価及び措置","fukusayou-hyouka",true,"第5章 医薬品の適正使用・安全対策","ch5-043","ch5-045",1784619074270]